This inventor holds 32 USPTO granted patents and 17 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Cephalon, Inc., Teva Pharmaceuticals Australia Pty Ltd, Cephalon Australia Pty. Ltd.. Active years: 2010-2026.
Location History:
- Drummoyne, AU (2010 - 2022)
- Macquarie Park, AU (2014 - 2024)
Company Filing History:
14 out of 248 
11 out of 14 
5 out of 9 Years Active: 2010-2026
Areas of Expertise:
Title: Innovator Spotlight: Anthony Gerard Doyle and His Contributions to Antibody Research
Introduction: Anthony Gerard Doyle, based in Drummoyne, Australia, is a prominent inventor with an impressive portfolio of 26 patents. His work primarily focuses on the development of innovative antibodies for treating various gastrointestinal diseases and other conditions. This article explores his latest patents, career highlights, and collaborations with other industry professionals.
Latest Patents: Anthony's groundbreaking contributions include patents for antibodies that specifically bind to TL1A, aimed at treating gastrointestinal diseases. These recombinantly expressed variant antibodies enhance affinity for TL1A and inhibit the interaction between TL1A and death receptor 3 (DR3). The therapeutic applications of these antibodies include treatments for asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, Crohn's disease, colitis, and more.
Additionally, his work on anti-CXCR2 antibodies has garnered attention. These human antibody molecules selectively bind to human CXCR2 and act as potent antagonists, preventing the recruitment of neutrophils into tissues while preserving circulating neutrophil numbers. The disclosures also extend to pharmaceutical compositions and various applications of these antibodies, reinforcing Anthony's role as a leader in this vital area of biomedical research.
Career Highlights: Throughout his career, Anthony has demonstrated a commitment to advancing medical science through innovative research. His experience includes significant roles at Teva Pharmaceuticals Australia Pty Ltd and Cephalon, Inc., where he contributed to the development of groundbreaking therapies.
Collaborations: Anthony has had the pleasure of collaborating with talented professionals in his field, including Adam Clarke and Matthew Pollard. These partnerships have helped foster a productive environment for innovation and creativity in antibody research.
Conclusion: Anthony Gerard Doyle is a remarkable inventor whose contributions to the field of antibody research have the potential to change the landscape of treatment for various diseases. With his continued dedication to innovation and collaboration, he is likely to make even more significant advancements in the future.